Colon-Targeted Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (10 November 2021) | Viewed by 18954
Special Issue Editor
Interests: colon-targeted drug delivery; prodrug; codrug; pathologically-targeted drug; molecular pharmacology of anti-colitic agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Colon-targeted drug delivery (CTDD) is achieved when a drug is prevented from being systemically absorbed and metabolized in the upper intestine, leading to delivery of a much greater amount of the intact drug to the large intestine. Compared with conventional drug delivery, colon-targeted delivery of a drug increases the concentration of the drug in the large intestine while reducing systemic absorption of the drug. Thus, CTDD should confer therapeutic and toxicological advantages for the treatment of colonic diseases such as inflammatory bowel disease. CTDD can also be utilized for chronotherapy and oral peptide therapy owing to the transit time to and low proteolytic activity in the large intestine. In addition, oral drug delivery systems aiming at sustained release of a drug in the GI tract can reach the large intestine, which affects the pharmacokinetics and therapeutic activity of the drug. This Special Issue welcomes any papers dealing with oral drug delivery system reaching the large intestine, including CTDD.
Prof. Dr. Yunjin Jung
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colon targeted drug delivery
- oral drug delivery
- colitis
- oral peptide therapy
- sustained release